Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Kulasekararaj, A. Hill, S. Rottinghaus, S. Langemeijer, R. Wells, F. González-Fernández, A. Gaya, J. Lee, E. Gutierrez, C. Piatek, J. Szer, A. Risitano, S. Nakao, Eric Bachman, L. Shafner, A. Damokosh, S. Ortiz, A. Röth, R. Latour (2019)
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.Blood, 133 6
(2020)
Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with zanubrutinib
Amy Gabbard, Garrett Booth (2020)
Cold Agglutinin DiseaseClinical Hematology International, 2
A. Risitano, Daniel Ricklin, Yijun Huang, E. Reis, Hui Chen, P. Ricci, Zhuoer Lin, Caterina Pascariello, M. Raia, M. Sica, L. Vecchio, F. Pane, F. Lupu, R. Notaro, R. Resuello, R. DeAngelis, John Lambris (2014)
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.Blood, 123 13
S. Berentsen, E. Ulvestad, R. Langholm, K. Beiske, H. Hjorth-Hansen, W. Ghanima, J. Sørbø, G. Tjønnfjord (2006)
Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.Haematologica, 91 4
Effects of oral, factor D inhibitor danicopan on transfusion rates in transfusion-dependent paroxysmal nocturnal hemoglobinuria (PNH) patients with an inadequate response to eculizumab: phase 2 study
Effectiveness of eculizumab treatment in patients aged ≥ 65 years with paroxysmal nocturnal hemoglobinuria (PNH): results from the International PNH Registry
A. Röth (2020)
Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Design of the First International, Prospective CAD Registry
J. Takeda, T. Miyata, K. Kawagoe, Y. Iida, Y. Endo, T. Fujita, Minoru Takahashi, T. Kitani, T. Kinoshita (1993)
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuriaCell, 73
P. Hillmen, J. Szer, I. Weitz, A. Röth, B. Hoechsmann, J. Panse, K. Usuki, M. Griffin, J. Kiladjian, C. Castro, H. Nishimori, L. Tan, M. Hamdani, Pascal Deschatelets, C. Francois, F. Grossi, A. Risitano, R. Latour (2020)
Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal HemoglobinuriaBlood, 136
S. Berentsen, U. Randen, G. Tjønnfjord (2015)
Cold agglutinin-mediated autoimmune hemolytic anemia.Hematology/oncology clinics of North America, 29 3
P. Nikitin, E. Rose, T. Byun, G. Parry, S. Panicker (2019)
C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In VitroThe Journal of Immunology, 202
S. Berentsen, K. Beiske, G. Tjønnfjord (2007)
Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapyHematology (Amsterdam, Netherlands), 12
M. Gertz (2007)
Management of cold haemolytic syndromeBritish Journal of Haematology, 138
(2020)
Pozelimab inhibits hemolysis in patients with paroxysmal nocturnal hemoglobinuria
(2020)
Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed MCL correlate with chemoresistance and call for innovative upfront therapy
S. Berentsen, T. Sundic (2015)
Red Blood Cell Destruction in Autoimmune Hemolytic Anemia: Role of Complement and Potential New Targets for TherapyBioMed Research International, 2015
L. Bylsma, A. Ording, A. Rosenthal, B. Öztürk, J. Fryzek, J. Arias, A. Röth, S. Berentsen (2019)
Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease.Blood advances, 3 20
(2020)
The PI3Kδ inhibitor ME-401 is well tolerated on intermittent schedule and produces a high rate of durable responses in relapsed/refractory indolent B-cell malignancies
A. Kulasekararaj, A. Risitano, J. Maciejewski, R. Notaro, P. Browett, J. Lee, Mingjun Huang, M. Geffner, R. Brodsky (2019)
A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab MonotherapyBlood
J. Lee, F. Fontbrune, Lily Lee, V. Pessoa, S. Gualandro, W. Füreder, V. Ptushkin, S. Rottinghaus, L. Volles, L. Shafner, R. Aguzzi, R. Pradhan, H. Schrezenmeier, A. Hill (2019)
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.Blood, 133 6
Ash Alizadeh, M. Eisen, R. Davis, Chishieva Ma, I. Lossos, A. Rosenwald, Jennifer Boldrick, H. Sabet, T. Tran, Xin Yu, J. Powell, Liming Yang, G. Marti, T. Moore, J. Hudson, Li-Sheng Lu, D. Lewis, R. Tibshirani, G. Sherlock, W. Chan, T. Greiner, D. Weisenburger, J. Armitage, R. Warnke, R. Levy, W. Wilson, M. Grever, J. Byrd, D. Botstein, P. Brown, L. Staudt (2000)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 403
(2020)
Zanubrutinib in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma
U. Jäger, W. Barcellini, C. Broome, M. Gertz, A. Hill, Q. Hill, B. Jilma, D. Kuter, M. Michel, M. Montillo, A. Röth, S. Zeerleder, S. Berentsen (2019)
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting.Blood reviews
(2020)
Safety of acalabrutinib monotherapy in mature B-cell malignancies: pooled analysis from clinical trials
S. Berentsen (2018)
How I manage patients with cold agglutinin diseaseBritish Journal of Haematology, 181
An interim analysis of a phase 2 study evaluating the efficacy, safety, and pharmacokinetics of intravenous ravulizumab 100 mg/mL formulation in patients with paroxysmal nocturnal hemoglobinuria
C. Broome, J. Cunningham, M. Mullins, Xiaohui Jiang, L. Bylsma, J. Fryzek, A. Rosenthal (2020)
Increased risk of thrombotic events in cold agglutinin disease: A 10‐year retrospective analysisResearch and Practice in Thrombosis and Haemostasis, 4
A. Risitano, S. Marotta, P. Ricci, L. Marano, C. Frieri, F. Cacace, M. Sica, A. Kulasekararaj, R. Calado, P. Scheinberg, R. Notaro, R. Latour (2019)
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMTFrontiers in Immunology, 10
M. Barros, A. Röth, W. Barcellini, T. Tvedt, Y. Miyakawa, D. Kuter, W. Hobbs, J. Su, X. Jiang, J. Arias, I. Weitz (2020)
SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IMPROVES QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: PATIENT-REPORTED OUTCOMES RESULTS OF THE PHASE 3 CARDINAL STUDYHematology, Transfusion and Cell Therapy, 42
A. Noy, S. Vos, C. Thieblemont, P. Martin, C. Flowers, F. Morschhauser, G. Collins, Shuo Ma, M. Coleman, S. Peles, Stephen Smith, J. Barrientos, Alina Smith, B. Munneke, I. Dimery, D. Beaupre, Robert Chen (2017)
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.Blood, 129 16
(2020)
Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory follicular lymphoma: interim analysis of a phase Ib/II trial
(2020)
Ibrutinib as second-line therapy is well tolerated and efficacious in frail patients with relapsed/refractory mantle cell lymphoma who are unsuitable for standard front-line therapies
S. Berentsen, G. Tjønnfjord (2012)
Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.Blood reviews, 26 3
(2020)
Phase 1/2 study of singleagent zanubrutinib in patients with relapsed/refractory marginal zone lymphoma
Hier steht eine Anzeige.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Oct 1, 2020
Keywords: oncology; medicine/public health, general
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.